Intercept Pharma to Cut 170 EmployeesBusiness, Clinical Trials, Complete Response Letter, Efficacy, FDA, Filings, Job Cuts, Non-alcoholic steatohepatitis (NASH), R&D, SEC, SharesShares of Intercept Pharmaceuticals fell more than 10 percent following a decision by the company’s board of directors to cut 25 percent of headcount. Read more September 2, 2020/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/09/Intercept-Pharma-to-Cut-170-Employees-in-Wake-of-CRL-for-NASH-Treatment-BioSpace-9-2-20.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2020-09-02 11:39:082020-09-02 12:31:25Intercept Pharma to Cut 170 Employees